Last reviewed · How we verify
Standard-DAPT of Ticagrelor plus aspirin
Ticagrelor and aspirin work together as dual antiplatelet agents to prevent blood clots by inhibiting platelet aggregation through different pathways.
Ticagrelor and aspirin work together as dual antiplatelet agents to prevent blood clots by inhibiting platelet aggregation through different pathways. Used for Acute coronary syndrome (ACS) with percutaneous coronary intervention (PCI), Secondary prevention of thrombotic cardiovascular events post-ACS.
At a glance
| Generic name | Standard-DAPT of Ticagrelor plus aspirin |
|---|---|
| Also known as | DAPT |
| Sponsor | Second Affiliated Hospital, School of Medicine, Zhejiang University |
| Drug class | Dual antiplatelet therapy (DAPT); P2Y12 inhibitor + cyclooxygenase inhibitor |
| Target | P2Y12 receptor (ticagrelor); cyclooxygenase-1 (aspirin) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Ticagrelor is a P2Y12 receptor antagonist that reversibly blocks ADP-induced platelet activation, while aspirin irreversibly inhibits cyclooxygenase (COX) to reduce thromboxane A2 production. Together, this dual antiplatelet therapy (DAPT) provides synergistic inhibition of platelet function, reducing thrombotic events in acute coronary syndromes and after percutaneous coronary intervention.
Approved indications
- Acute coronary syndrome (ACS) with percutaneous coronary intervention (PCI)
- Secondary prevention of thrombotic cardiovascular events post-ACS
Common side effects
- Bleeding (major and minor)
- Dyspnea
- Bradycardia
- Gastrointestinal bleeding
- Intracranial hemorrhage
Key clinical trials
- Safety and Efficacy of De-escalation Dual Antiplatelet Therapy After BioFreedom™ Stenting in ACS Patients With Moderate-to-high Ischemic and High Bleeding Risk (NA)
- Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO IV-EPIC 38) (NA)
- PCI With Guideline-Directed Medical Therapy for HFpEF Patients With Ischemic Cardiomyopathy (NA)
- Safety and Efficacy of Very Short DAPT in Older Patients Undergoing PCI (PHASE3)
- Algorithm-based Tailoring of Dual Antiplatelet Therapy to Improve Outcomes Following Percutaneous Coronary Interventions (NA)
- Short-Term Dual Antiplatelet Therapy With Early Transi-tion to Low-dose Antiplatelet Monotherapy Using Ti-cagRelor in Chronic Coronary Artery Disease (PHASE4)
- Ischemic and Bleeding Outcomes After Angiolite Stent Implantation and an Abbreviated Dual Antiplatelet Therapy (PHASE3)
- Pharmacogenomics in Stroke: Feasibility of CYP2C19 Testing (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: